文献速递浆细胞疾病

联合BRAF/MEK抑制治疗BRAFV600E突变多发性骨髓瘤的2期临床试验

A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
PubMed 文献 · Blood · 2023-01-01

这项前瞻性单臂、开放标签、多中心2期试验评估恩科拉非尼联合比美替尼治疗携带BRAFV600E突变的复发/难治性多发性骨髓瘤(RRMM)的疗效与安全性。共入组12例中位既往5线治疗的患者,总缓解率为83.3%,中位无进展生存期5.6个月,24个月总生存率55%。

要点

  • 恩科拉非尼450 mg每日一次联合比美替尼45 mg每日两次治疗BRAFV600E突变RRMM。
  • 12例患者总缓解率83.3%,10例至少达部分缓解,中位无进展生存期5.6个月。
  • 24个月总生存率55%,耐药由RAS突变及BRAF位点结构变异驱动。

核心结论

  • 这是首个前瞻性临床试验证明联合BRAF/MEK抑制对BRAFV600E突变RRMM高度有效,代表该病成功的靶向精准医学方法。

研究设计与样本

  • 前瞻性单臂、开放标签、多中心2期试验,评估恩科拉非尼联合比美替尼治疗携带BRAFV600E突变的复发/难治性多发性骨髓瘤(RRMM)。
  • 患者接受恩科拉非尼450 mg每日一次和比美替尼45 mg每日两次。
  • 主要终点为开始治疗后第一年内根据国际骨髓瘤工作组标准达到的总缓解率。
  • 共入组12例RRMM患者,中位既往治疗线数为5线。
  • 试验注册于www.clinicaltrials.gov,编号#NCT02834364。

主要发现

  • 总缓解率为83.3%,10例患者至少达到部分缓解。
  • 中位无进展生存期为5.6个月,24个月总生存率为55%。
  • 出现的治疗耐药由RAS突变和涉及BRAF位点的结构变异驱动。

关键数值与推荐

  • 总缓解率83.3%,10例患者至少达到部分缓解。
  • 中位无进展生存期5.6个月,24个月总生存率55%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Activating BRAF mutations are found in a small subset of patients with newly diagnosed multiple myeloma, but prevalence increases in late-stage, refractory disease, and the mutations are associated with adverse outcome. This prospective single-arm, open-label, multicenter phase 2 trial assessed the efficacy and safety of combined BRAF/MEK inhibition, using encorafenib and binimetinib, in patients with relapsed/refractory multiple myeloma (RRMM) carrying a BRAFV600E mutation. Patients received 450 mg encorafenib once daily and binimetinib 45 mg twice daily. The primary end point was the overall response rate achieved within the first year after start of treatment according to International Myeloma Working Group criteria. Twelve RRMM patients with a median of 5 prior lines of therapy were enrolled. The overall response rate was 83.3%, with 10 patients achieving at least a partial response. The median progression-free survival was 5.6 months, and overall survival was 55% at 24 months. Emerging resistance to therapy was driven by RAS mutations and structural variants involving the BRAF locus. This is the first prospective clinical trial to demonstrate that combined BRAF/MEK inhibition is highly effective in patients with BRAFV600E-mutated RRMM, and it represents a successful targeted precision medicine approach in this disease. This trial was registered at www.clinicaltrials.gov as #NCT02834364.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Giesen N, Chatterjee M, Scheid C, et al. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood. 2023. PMID: 36608320. doi:10.1182/blood.2022017789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。